01—Abstract
Summary
Summary of the 8-K filed October 15, 2025. Cited figures are marked; the original filing is the authoritative source.
On October 15, 2025, BD (Becton, Dickinson and Company) disclosed that Chief Financial Officer Christopher DelOrefice will leave the company effective December 5, 2025, to pursue a new professional opportunity.
Vitor Roque, Senior Vice President of Finance, Business Units and Corporate FP&A, has been named interim CFO effective upon DelOrefice's departure, and the company is searching for a permanent successor. The filing states the departure is not related to any disagreement on financial statements, internal controls, operations, policies or practices. Alongside the leadership change, BD furnished preliminary, unaudited fiscal Q4 and full-year 2025 revenue.
Fiscal Q4 revenue was approximately $5.9 billiona, up 8.3% reported, 7.0% currency-neutral and 3.9% organic. Full-year revenue was approximately $21.8 billion, up 8.2% reported, 7.7% adjusted currency-neutral and 2.9% organic. Management said results were hurt more than expected by Pharmaceutical Systems (vaccines) and Biosciences academic and government research, while BD Interventional, Advanced Patient Monitoring and Medication Delivery Solutions grew strongly.
The company expects full-year FY2025 adjusted diluted EPS at or above the midpoint of prior guidance. For investors, the key takeaways are the CFO transition during a period of strategic repositioning, the softer organic growth in certain end markets, and the reliance on preliminary, unaudited figures that may change at final close.
Management plans to discuss FY2026 expectations and its 'New BD' strategy on the November 6, 2025 earnings call. The filing also references the proposed combination of BD's Biosciences and Diagnostic Solutions business with Waters, which carries completion uncertainty.
02—Key points
Key Highlights
- CFO transition: Christopher DelOrefice will depart as EVP and CFO effective December 5, 2025, to pursue a new opportunity; no disagreement with the company on financial or operational matters is cited.
- Interim CFO: Vitor Roque (SVP Finance, Business Units and Corporate FP&A, age 43, with BD since 2019 in finance roles) becomes interim principal financial officer; a permanent search is underway.
- Q4 FY2025 preliminary revenue of ~$5.9B: +8.3% reported, +7.0% currency-neutral, +3.9% organic (organic excludes ~$170M of inorganic revenue from Advanced Patient Monitoring).
- Full-year FY2025 preliminary revenue of ~$21.8B: +8.2% reported, +7.7% adjusted currency-neutral, +2.9% organic, with organic growth affected by the acquisition contribution.
- Weakness flagged in Pharmaceutical Systems (vaccines) and Biosciences academic and government research, which the CEO said had a greater-than-anticipated impact in the quarter.
- FY2025 adjusted diluted EPS guidance: expected at or above the midpoint of previously issued guidance.
- Next catalysts: Q4/FY2025 earnings webcast on November 6, 2025 at 8 a.m. ET, where management plans to outline its 'New BD' strategy and FY2026 expectations; the figures are unaudited and subject to change.
03—Questions
Frequently Asked Questions
Why is the CFO leaving, and does it signal a problem with the financials?
The filing says DelOrefice is leaving to pursue a new professional opportunity and that the departure is not the result of any disagreement with the company on financial statements, internal control over financial reporting, operations, policies or practices. Nothing in the filing suggests an accounting or control issue, though investors may still watch the transition closely.
Who is replacing the CFO, and what is the transition timeline?
Vitor Roque, currently SVP of Finance, Business Units and Corporate FP&A, will serve as interim CFO and principal financial officer effective upon DelOrefice's departure on December 5, 2025. He has been with BD for about two decades, including as CFO of the BD Medical segment, and BD has begun a search for a permanent CFO.
How did BD perform in fiscal 2025, and where were the weak spots?
Preliminary full-year revenue was about $21.8 billion, up 8.2% reported and 2.9% organic. Q4 revenue was about $5.9 billion, up 8.3% reported and 3.9% organic. Management cited greater-than-expected pressure in Pharmaceutical Systems (vaccines) and Biosciences academic and government research, and strength in BD Interventional, Advanced Patient Monitoring and Medication Delivery Solutions.
Are these revenue figures final, and how should investors use them?
No. The figures are preliminary, unaudited, prepared internally, and subject to completion of closing and audit procedures, so they may differ materially from final results. The company also said they are not a comprehensive statement of results. Investors should wait for the full results and the November 6, 2025 earnings release before drawing firm conclusions.
What should investors expect next from BD?
Management said it will share more on its 'New BD' strategy, further actions to unlock value, and fiscal 2026 expectations on the November 6, 2025 earnings call. The filing also references the proposed combination of the Biosciences and Diagnostic Solutions business with Waters, which may not be completed as described or at all.
04—Continue